Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Revvity Omics, |
RCV005632340 | SCV006320833 | uncertain significance | not provided | 2023-11-16 | criteria provided, single submitter | clinical testing | |
| Fulgent Genetics, |
RCV000765566 | SCV000896881 | uncertain significance | Dilated cardiomyopathy 1G; Autosomal recessive limb-girdle muscular dystrophy type 2J; Tibial muscular dystrophy; Myopathy, myofibrillar, 9, with early respiratory failure; Early-onset myopathy with fatal cardiomyopathy; Hypertrophic cardiomyopathy 9 | 2018-10-31 | criteria provided, single submitter | clinical testing | |
| Labcorp Genetics |
RCV000229588 | SCV000286745 | uncertain significance | Dilated cardiomyopathy 1G; Autosomal recessive limb-girdle muscular dystrophy type 2J | 2016-04-05 | criteria provided, single submitter | clinical testing | |
| Prevention |
RCV004541382 | SCV004760508 | uncertain significance | TTN-related disorder | 2024-02-15 | no assertion criteria provided | clinical testing | The TTN c.58561G>A variant is predicted to result in the amino acid substitution p.Glu19521Lys. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.015% of alleles in individuals of Latino descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |